8-K: IDEAYA Biosciences Reports Strong Clinical Data Across Three Oncology Programs

IDEAYA Biosciences announced positive interim clinical data for IDE849 in SCLC, darovasertib in uveal melanoma, and IDE397 in urothelial cancer.

Summary

• IDEAYA Biosciences and Jiangsu Hengrui Pharmaceuticals presented initial Phase 1 data for IDE849 (DLL3 TOP1 ADC) in small cell lung cancer (SCLC) at the IASLC 2025 World Conference on Lung Cancer.
• In 71 evaluable refractory SCLC patients (2L+), IDE849 demonstrated an overall response rate (ORR) of 73.2% and a disease control rate (DCR) of 93.0% across doses ≥ 2.4 mg/kg.
• A confirmed ORR of 66.7% and DCR of 100% was observed in SCLC patients with baseline brain metastasis (n=18) at doses ≥ 2.4 mg/kg.
• Median progression-free survival (PFS) was 6.7 months across all lines of treatment at doses ≥ 2.4 mg/kg (n=86), with median PFS not yet reached in 2L patients (n=42).
• The safety profile for IDE849 was manageable, with Grade 3 or higher treatment-related adverse events (TRAEs) in 48% of 100 patients, a 15% dose reduction rate, and a 2% treatment-related discontinuation rate, with no treatment-related deaths.
• The company presented positive interim Phase 2 data for darovasertib in the neoadjuvant setting of primary uveal melanoma (UM) from the OptimUM-09 trial.
• 76% (16/21) of evaluable patients achieved ≥20% ocular tumor shrinkage, and 48% (10/21) achieved ≥20% reduction in simulated radiation dose to key visual structures.
• 65% (13/20) of patients observed visual improvement, with a median gain of 6 letters, and 67% (14/21) observed a reduction in their 3-year risk of legal blindness.
• Darovasertib's safety profile showed mostly Grade 1 and 2 TRAEs, with approximately 10% (4/39) Grade 3 or higher, and four patients discontinuing treatment due to TRAEs.
• Initial Phase 1/2 combination trial data for IDE397 (MAT2A inhibitor) and Trodelvy in late-line MTAP-deletion urothelial cancer (UC) were also presented.
• In 16 evaluable patients, ORR was 33% at Dose Level 1 (IDE397 15mg + Trodelvy 10mg/kg) and 57% at Dose Level 2 (IDE397 30mg + Trodelvy 7.5mg/kg).
• The combination's safety profile was consistent with known adverse events of both drugs as single agents, with no treatment-related serious adverse events observed at Dose Level 2.

Sentiment

Score: 9

Explanation: The filing reports positive clinical data across three distinct oncology programs, showing strong efficacy signals and manageable safety profiles in difficult-to-treat cancers. The initiation of a Phase 3 trial for darovasertib and promising results for IDE849 and IDE397 represent significant advancements for the company.

Positives

• IDE849 demonstrated robust overall response rate (73.2%) and disease control rate (93.0%) in refractory SCLC patients, including those with brain metastasis.
• IDE849 showed a median progression-free survival of 6.7 months, which is promising for a refractory SCLC population.
• The safety profile of IDE849 was manageable, with a low treatment-related discontinuation rate (2%) and no reported treatment-related deaths.
• Darovasertib achieved significant ocular tumor shrinkage (76% of patients ≥20% shrinkage) in primary uveal melanoma.
• Darovasertib treatment led to a reduction in simulated radiation dose to critical eye structures (48% of patients ≥20% reduction), potentially improving visual outcomes.
• Meaningful visual gains were observed with darovasertib, with 65% of patients showing improvement and a median gain of 6 letters.
• Darovasertib reduced the long-term risk of legal blindness, with 67% of patients observing a reduction in their 3-year risk.
• The Phase 3 registration-enabling OptimUM-10 trial for darovasertib in neoadjuvant primary UM was initiated in Q2 2025, indicating strong progress.
• IDE397 in combination with Trodelvy showed a promising overall response rate of 57% at Dose Level 2 in late-line MTAP-deletion urothelial cancer, a population with no FDA-approved therapies.
• The safety profile of the IDE397 and Trodelvy combination was manageable and consistent with the known profiles of the individual agents, with no serious TRAEs at Dose Level 2.

Negatives

• IDE849 had a Grade 3 or higher treatment-related adverse event rate of 48% across all patients and dose levels.
• 15% of IDE849 patients required dose reduction due to treatment-related adverse events.
• 14.1% of IDE849 overall responses are still pending confirmation, and some patients have limited follow-up, indicating the data is not fully mature.
• Darovasertib treatment led to Grade 3 or higher TRAEs in approximately 10% of patients, and four patients discontinued treatment due to TRAEs.
• The IDE397 and Trodelvy combination reported Grade 3 or greater TRAEs, including anemia, neutropenia, asthenia, and diarrhea.

Risks

• Uncertainties inherent in the drug development process, including the early stage of development for some programs.
• Challenges associated with designing and conducting preclinical and clinical trials.
• Risks related to regulatory approval processes and the timing of regulatory filings.
• Challenges involved in manufacturing drug products.
• The company's ability to successfully establish, protect, and defend its intellectual property.
• Actual results could differ significantly from forward-looking statements due to substantial risks and uncertainties.

Future Outlook

The company anticipates further clinical trial updates, including additional darovasertib data at the ESMO meeting in October 2025, and the selection of a recommended Phase 2 dose for IDE397 + Trodelvy by the end of 2025, with a subsequent update in the first half of 2026. They also expect to continue evaluating TOP1-payload based ADCs in SCLC and other DLL3-upregulated solid tumors.

Industry Context

The positive data for IDE849, a DLL3 TOP1 ADC, positions IDEAYA in the competitive small cell lung cancer market, where new treatment options are highly sought after for refractory patients. Darovasertib's neoadjuvant data for uveal melanoma addresses a significant unmet need for eye-sparing treatments, potentially improving patient outcomes beyond current standards. The IDE397 + Trodelvy combination targets MTAP-deletion cancers, a genetically defined subset with no FDA-approved therapies, representing a novel approach in urothelial cancer and potentially NSCLC. These developments align with the industry trend towards targeted therapies and antibody-drug conjugates (ADCs) for difficult-to-treat cancers.

Comparison to Industry Standards

• IDE849 (SCLC): The 73.2% ORR and 6.7 months median PFS in refractory SCLC (2L+) are highly encouraging. For comparison, standard second-line SCLC treatments like topotecan typically show ORRs in the range of 10-25% and PFS of 3-4 months. Newer agents like lurbinectedin have shown an ORR of 35% and median PFS of 3.5 months in second-line SCLC. The observed efficacy for IDE849, especially the 66.7% confirmed ORR in patients with brain metastasis, appears significantly better than current options for this challenging patient population.
• Darovasertib (Uveal Melanoma): The 76% ocular tumor shrinkage and 48% reduction in radiation dose to key visual structures in neoadjuvant primary UM are strong indicators of potential benefit. Current standard of care, plaque brachytherapy, often leads to vision loss. While direct comparative data for neoadjuvant PKC inhibitors are limited, these results suggest a substantial improvement in tumor control and vision preservation compared to historical outcomes with brachytherapy alone. The initiation of a Phase 3 trial (OptimUM-10) further validates the potential.
• IDE397 + Trodelvy (MTAP-Deletion UC): An ORR of 57% at DL2 in late-line MTAP-deletion UC is notable, especially given the lack of FDA-approved therapies for this specific genetic subset. For comparison, Trodelvy as a monotherapy in heavily pretreated metastatic UC (not specifically MTAP-deletion) has shown an ORR of around 27%. The combination appears to significantly enhance response rates in this difficult-to-treat population.

Stakeholder Impact

• Shareholders: Positive clinical data across multiple programs could lead to increased investor confidence and potential share price appreciation, especially with a Phase 3 trial initiated and promising early-stage results.
• Patients: The reported data offers hope for new, effective treatment options for patients with refractory small cell lung cancer, primary uveal melanoma (with potential for vision preservation), and late-line MTAP-deletion urothelial cancer, addressing significant unmet medical needs.
• Healthcare Providers: Successful development of these therapies could provide new tools for oncologists to treat challenging cancers, potentially improving patient outcomes and quality of life.
• Partners (Jiangsu Hengrui Pharmaceuticals, Gilead Sciences, Inc.): The positive data validates the collaborations and could strengthen future partnerships and potential commercialization efforts.

Next Steps

• Present additional darovasertib data from over 90 patients in both plaque brachytherapy and enucleation cohorts of the OptimUM-09 trial at the European Society of Medical Oncology (ESMO) meeting on October 17-21, 2025.
• Target selection of recommended Phase 2 dose for IDE397 and Trodelvy combination by the end of 2025.
• Plan the next update for IDE397 and Trodelvy combination at a medical conference in the first half of 2026.
• Continue clinical trials to evaluate TOP1-payload based ADCs in SCLC and other DLL3-upregulated solid tumors.

Key Dates

Recommendation

The filing presents overwhelmingly positive clinical data for three distinct oncology assets, each addressing significant unmet medical needs in challenging cancer types. IDE849 shows robust efficacy in refractory SCLC, darovasertib demonstrates tumor shrinkage and vision preservation in primary uveal melanoma with a Phase 3 trial already initiated, and IDE397 in combination with Trodelvy yields impressive response rates in late-line MTAP-deletion UC. These results significantly de-risk the company's pipeline and indicate strong therapeutic potential, justifying a "strong buy" recommendation for long-term investors.

Keywords

IDEAYA Biosciences, IDE849, Darovasertib, IDE397, Small Cell Lung Cancer, Uveal Melanoma, Urothelial Cancer, ADC, DLL3, TOP1 inhibitor, PKC inhibitor, MAT2A inhibitor, Clinical Trial, Phase 1, Phase 2, Oncology, Biotechnology, Drug Development, Cancer Treatment, SEC Filing, 8-K